Gastric adenocarcinoma

Related records

Broader conditions (20)

• Adenocarcinoma
• Cancer
• Cancer or benign tumor
• Carcinoma
• Digestive system cancer
• Digestive system carcinoma
• Digestive system disorder
• Digestive system neoplasm
• Disease
• Disease by body system or component
• Disease by etiologic mechanism
• Epithelial neoplasm
• Gastric cancer
• Gastric carcinoma
• Gastric neoplasm
• Glandular cell neoplasm
• Human disease
• Neoplasm
• Neoplastic disease or syndrome
• Stomach disorder

Narrower conditions (11)

• CTNNA1-related diffuse gastric and lobular breast cancer syndrome
• Diffuse gastric adenocarcinoma
• Gastric cardia adenocarcinoma
• Gastric intestinal type adenocarcinoma
• Gastric linitis plastica
• Gastric papillary adenocarcinoma
• Gastric tubular adenocarcinoma
• Hereditary diffuse gastric adenocarcinoma
• Microinvasive gastric cancer
• Mucinous gastric adenocarcinoma
• Signet ring cell gastric adenocarcinoma

Trials (382)

• [18F]F-FAPI PET/CT and Laparoscopy in Staging Advanced Gastric Cancer
• 89Zr-girentuximab for PET Imaging of CAIX Positive Solid Tumors
• A Clinical Trial of Apatinib Plus Docetaxel in Locally Advanced or Metastatic Gastric or GEJ Adenocarcinoma
• A Clinical Trial of D1+ Versus D2 Distal Gastrectomy for Stage IB & II Advanced Gastric Cancer
• A Multicentre Observational Cross-Sectional Study of The Gastric Precancerous Epithelial Pathway Using High-Definition Endoscopy And Histopathology In India
• A Phase 1 Study Evaluating DISP-10 in Participants With Advanced Gastrointestinal Cancers
• A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors
• A Phase 1a/1b FIH Study of PY159 and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors
• A Phase 2 Study of Ramucirumab (LY3009806) in Participants With Gastric or Gastroesophageal Junction (GEJ) Cancer
• A Phase Ib Trial Evaluating the Safety and Activity of Neoadjuvant Combination of Tislelizumab Plus FLOT for Resectable Esophagogastric Adenocarcinoma
• A Phase II Clinical Study of Surufatinib Combined With Sintilimab in the Treatment of Advanced Gastric Cancer
• A Phase II Study of Perioperative Paclitaxel in Patients With Gastric Adenocarcinoma and Carcinomatosis or Positive Cytology
• A Phase II, Multicenter, Randomized, Controlled Clinical Study Comparing the Efficacy and Safety of Sintilimab Plus SOX Versus SOX Alone as Adjuvant Therapy for PD-L1-Positive, Stage pN3 Gastric Cancer
• A Phase III Randomized Study in CLDN18.2-positive Unresectable Locally Advanced Gastric Cancer Patients
• A Randomized, Multicenter Phase II Basket Study of Hypofractionated Radiotherapy/Stereotactic Body Radiotherapy Followed by Immunotherapy-Based Systemic Therapy +/- L. Rhamnosus M9 for the First-Line Treatment of Advanced Digestive System Malignancies.
• A Real World Study of the Treatment of Gastric Adenocarcinoma With Huachansu
• A Safety Study of SGN-2FF for Patients With Advanced Solid Tumors
• A Study Collecting Health Information to Understand and Prevent Gastric Cancer
• A Study of agenT-797 in Combination With Botensilimab, Balstilimab, Ramucirumab, and Paclitaxel for People With Esophageal, Gastric, or Gastro-esophageal Junction Cancer
• A Study of AK104 in the First-line Treatment of Locally Advanced Unresectable or Metastatic G/GEJ Adenocarcinoma

Approved drugs (6)

• Capecitabine
• Docetaxel
• Ramucirumab
• Tislelizumab
• Trastuzumab
• Zolbetuximab

Drugs in development (97)

• ABGN-107 Phase 1
• Adavosertib Phase 2
• Adebrelimab Phase 2
• Albumin human Phase 3
• Alofanib Phase 1
• Alovudine F-18 Phase 2
• AMG-337 Phase 2
• Andecaliximab Phase 3
• Atezolizumab Phase 2
• Avelumab Phase 3
• Bemarituzumab Phase 2
• Bevacizumab Phase 3
• Cadonilimab Phase 2
• Camrelizumab Phase 3
• Capivasertib Phase 2
• Carbamazepine Phase 3
• Catumaxomab Phase 3
• Cetuximab Phase 3
• Cisplatin Phase 3
• Cobimetinib Phase 1

Other linked drugs (2)

• Eprenetapopt
• Tucatinib